GLP-1 receptor agonists show little effect on obesity-related cancer risk
1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant ...
Tag: obesity
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with ...
Body composition measures from magnetic resonance imaging scans may be associated with adverse health outcomes
1. In this prospective cohort study, an artificial intelligence tool was used to segment magnetic resonance imaging scans into body ...
The Scan by 2 Minute Medicine®: Leucovorin autism update, Oura Ring FDA scrutiny, Lilly oral GLP-1 trial, and Florida vaccine mandate repeal
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Leucovorin ...
Wegovy survey finds decline in constant food thoughts and improved well being
1. Survey of 550 adults found a 46 percent reduction in constant food thoughts after starting Wegovy. 2. 64 percent ...
FDA escalates warning letters over misleading drug advertising
1. Thousands of warning letters and 100 cease and desist orders mark the most aggressive FDA enforcement in years. 2. ...
What Is the Cricothyroid Membrane and Why It Matters in Medicine
What Is the Cricothyroid Membrane The cricothyroid membrane (CTM) is a small but essential structure in the neck. It provides ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup: Enbumyst Nasal Spray Approval, FDA Targets Drug Ads, Samsung BioLogics Contract, Wegovy Mental Health Benefits [September 17 2025]
Corstasis’ Enbumyst nasal spray approved for edema The Food and Drug Administration has approved Enbumyst, a bumetanide nasal spray, for ...
Semaglutide and tirzepatide may be cost-effective for knee osteoarthritis in patients with obesity
1. In this microsimulation model, the two glucagon-like peptide-1 receptor agonists were shown to be cost-effective when added to usual ...
Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis
1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo. 2. MASH resolution without worsened fibrosis was ...
